Afatinib Side Effects and Safety Management

　　Afatinib is an irreversible EGFR-TKI used in EGFR-mutated advanced or metastatic non-small cell lung cancer and,in selected squamous NSCLC settings,per labeling.By blocking EGFR/ErbB family signaling it slows tumor growth,but the same pathway inhibition produces predictable toxicities in skin,gastrointestinal mucosa,nails,and sometimes lung or liver.

　　Common,usually manageable reactions​

　　Diarrhea:often appears in the first two weeks.Mild cases need hydration,small frequent meals,and antidiarrheals per protocol;persistent diarrhea beyond 48 hours,fever,blood in stool,or signs of dehydration requires medical review.

　　Skin rash:acneiform papules,dryness,pruritus,desquamation;paronychia may develop later.Use gentle cleansers,fragrance-free moisturizers,broad-spectrum sunscreen,loose clothing,and avoid picking nails.Moderate-severe or infected rash may need topical/oral antibiotics or dose adjustment.

　　Oral and nail toxicity:stomatitis,mucositis,angular cheilitis,periungual inflammation.Soft-bristle brushing,saline rinses,and dental hygiene help;painful ulcers or infected nail folds should be evaluated.

　　Gastrointestinal and general symptoms:nausea,reduced appetite,occasional vomiting,fatigue,headache,myalgia/arthralgia.Symptom diary and conservative measures are usually sufficient for mild grades.

　　Serious reactions requiring urgent action​

　　Pulmonary:new or worsening cough,dyspnea,chest pain,or fever should trigger evaluation for interstitial lung disease/pneumonitis.Suspect ILD warrants holding afatinib;confirmed ILD generally leads to permanent discontinuation after alternative causes are excluded.

　　Hepatotoxicity:marked transaminase elevation,hyperbilirubinemia,jaundice,or severe fatigue.Baseline and periodic liver tests are essential;severe injury requires stopping the drug.

　　Dehydration/electrolyte loss:severe diarrhea/vomiting can cause prerenal azotemia,hypotension,and electrolyte disturbances;assess hydration,replace fluids/electrolytes.

　　Ocular toxicity:blurred vision,eye pain,photophobia,severe dry eye,or keratitis.Persistent symptoms need ophthalmology review and possibly drug interruption.

　　Cardiac/hematologic:arrhythmias,heart-failure symptoms,significant anemia,or thrombocytopenia are less common but need urgent assessment.

　　Patient self-management and monitoring​

　　Before starting therapy,the team should explain expected side effects,when to call,and how to use antidiarrheal agents.Afatinib is typically taken on an empty stomach—at least 1 hour before or 3 hours after food—and never self-titrated.Keep a symptom log for stool frequency,rash area/itch,oral pain,weight,temperature,and breathing.Schedule labs per oncologist:CBC,LFTs,renal/electrolytes as needed,and imaging when disease or toxicity warrants.

　　Dose-adjustment principles​

　　Clinicians grade events using standard toxicity criteria.Grade 1—2 tolerated symptoms usually continue with supportive care;diarrhea>48 hours,rash>7 days,prolonged/unbearable grade 2,or grade≥3 generally prompt interruption,then rechallenge at a lower dose in 10mg steps once resolved to grade 0—1.If the patient cannot tolerate the lowest effective dose,discontinuation and alternative EGFR-TKI/oncologic strategy are considered.P-gp inhibitors/inducers may change exposure;dosing intervals or dose changes should be physician-directed,not self-managed.